Renaissance Technologies (RenTech)'s AZN Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC) currently holds 98,272 shares of AstraZeneca PLC (AZN) worth $15.87 M, representing 0.02% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 51 quarters.
Based on 13F filings since 2013, Renaissance Technologies (RenTech) has maintained a long-term strategic position in AZN, representing a significant commitment to this investment thesis. Largest addition occurred in Q3 2021, adding 3.34 M shares. Largest reduction occurred in Q4 2016, reducing 2.15 M shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s AstraZeneca PLC (AZN) Holding Value Over Time
Track share changes against reported price movement
Quarterly AstraZeneca PLC (AZN) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q3 2026 | +98,272 | New Buy | 98,272 | $161.47 |
| Q3 2025 | -651,886 | Sold Out | 0 | $0.00 |
| Q2 2025 | +502,286 | Add 335.75% | 651,886 | $139.76 |
| Q1 2025 | +139,415 | Add 1368.83% | 149,600 | $147.00 |
| Q4 2024 | -142,269 | Reduce 93.32% | 10,185 | $131.04 |
| Q3 2024 | +123,704 | Add 430.27% | 152,454 | $155.82 |
| Q2 2024 | -316,222 | Reduce 91.67% | 28,750 | $155.98 |
| Q1 2024 | -11,750 | Reduce 3.29% | 344,972 | $135.50 |
| Q4 2023 | -515,116 | Reduce 59.08% | 356,722 | $134.70 |
| Q3 2023 | +250,856 | Add 40.40% | 871,838 | $135.44 |
| Q2 2023 | -484,019 | Reduce 43.80% | 620,982 | $0.14 |
| Q1 2023 | -703,922 | Reduce 38.91% | 1.11 M | $0.14 |
| Q4 2022 | -1.09 M | Reduce 37.62% | 1.81 M | $0.14 |
| Q3 2022 | -29,750 | Reduce 1.02% | 2.9 M | $109.68 |
| Q2 2022 | +648,622 | Add 28.44% | 2.93 M | $132.14 |
| Q1 2022 | -628,500 | Reduce 21.60% | 2.28 M | $132.68 |
| Q4 2021 | -532,774 | Reduce 15.48% | 2.91 M | $116.50 |
| Q3 2021 | +3.34 M | Add 3313.18% | 3.44 M | $120.12 |
| Q2 2021 | +91,400 | Add 967.20% | 100,850 | $119.80 |
| Q1 2021 | -173,600 | Reduce 94.84% | 9,450 | $99.47 |
| Q4 2020 | -142,094 | Reduce 43.70% | 183,050 | $99.98 |
| Q3 2020 | -1.37 M | Reduce 80.82% | 325,144 | $109.60 |
| Q2 2020 | -197,475 | Reduce 10.43% | 1.69 M | $105.78 |
| Q1 2020 | +1.46 M | Add 340.36% | 1.89 M | $89.32 |
| Q4 2019 | +356,450 | Add 486.29% | 429,750 | $99.72 |
| Q3 2019 | -627,018 | Reduce 89.53% | 73,300 | $89.14 |
| Q2 2019 | -221,832 | Reduce 24.06% | 700,318 | $82.56 |
| Q1 2019 | +922,150 | New Buy | 922,150 | $80.86 |
| Q4 2018 | -13,600 | Sold Out | 0 | $0.00 |
| Q3 2018 | -478,950 | Reduce 97.24% | 13,600 | $79.12 |
| Q2 2018 | -22,950 | Reduce 4.45% | 492,550 | $70.22 |
| Q1 2018 | +463,550 | Add 892.30% | 515,500 | $69.94 |
| Q4 2017 | +51,950 | New Buy | 51,950 | $69.39 |
| Q3 2017 | -65,350 | Sold Out | 0 | $0.00 |
| Q2 2017 | +65,350 | New Buy | 65,350 | $68.19 |
| Q1 2017 | -697,400 | Sold Out | 0 | $0.00 |
| Q4 2016 | -2.15 M | Reduce 75.54% | 697,400 | $54.64 |
| Q3 2016 | -131,700 | Reduce 4.41% | 2.85 M | $65.72 |
| Q2 2016 | +141,650 | Add 4.99% | 2.98 M | $60.38 |
| Q1 2016 | +361,550 | Add 14.58% | 2.84 M | $56.32 |
| Q4 2015 | -246,600 | Reduce 9.04% | 2.48 M | $67.90 |
| Q3 2015 | -1.21 M | Reduce 30.71% | 2.73 M | $63.64 |
| Q2 2015 | +780,200 | Add 24.73% | 3.93 M | $63.71 |
| Q1 2015 | +866,500 | Add 37.87% | 3.15 M | $68.43 |
| Q4 2014 | +440,800 | Add 23.86% | 2.29 M | $70.38 |
| Q3 2014 | +52,300 | Add 2.91% | 1.85 M | $71.44 |
| Q2 2014 | +365,800 | Add 25.60% | 1.79 M | $74.31 |
| Q1 2014 | -1.29 M | Reduce 47.37% | 1.43 M | $64.88 |
| Q4 2013 | -198,400 | Reduce 6.81% | 2.72 M | $59.37 |
| Q3 2013 | -511,900 | Reduce 14.94% | 2.91 M | $51.93 |
| Q2 2013 | +3.43 M | Add 0.00% | 3.43 M | $47.30 |
Renaissance Technologies (RenTech)'s AstraZeneca PLC Investment FAQs
Renaissance Technologies (RenTech) first purchased AstraZeneca PLC (AZN) in Q2 2013, acquiring 3,425,700 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held AstraZeneca PLC (AZN) for 51 quarters since Q2 2013.
Renaissance Technologies (RenTech)'s largest addition to AstraZeneca PLC (AZN) was in Q2 2013, adding 3,425,700 shares worth $162.04 M.
According to the latest 13F filing for Q3 2026, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC, owns 98,272 shares of AstraZeneca PLC (AZN), valued at approximately $15.87 M.
As of the Q3 2026 filing, AstraZeneca PLC (AZN) represents approximately 0.02% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in AstraZeneca PLC (AZN) was 3,934,600 shares, as reported at the end of Q2 2015.